Daily close, T-120 (10/9/24) through T+5. Run-up high $59.18 on 11/19/24, low $42.54 on 1/16/25 (T-120 to T-1). FDA decision 3/26/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 12, 2025, 14 days before the decision date, at-the-money options priced a move of ±44.2% through Apr 17, 2025 (the first listed expiry after the decision; ATM implied volatility 182%). The stock closed -2.2% at the first close across the decision and +36.4% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was VYKAT XR (diazoxide choline) extended-release tablets approved by the FDA?
Yes. The FDA approved the application for VYKAT XR (diazoxide choline) extended-release tablets on March 26, 2025. The primary source is linked on this page.
What was VYKAT XR (diazoxide choline) extended-release tablets under FDA review for?
The application covered Prader-Willi syndrome (PWS). The FDA approved the application on March 26, 2025.
How did SLNO stock react to the FDA decision?
On the decision day SLNO moved -2.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.